tb-402
mAbexperimental
Clinical trial activity
5 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Mar 1, 2007 (NCT00612196)
Timeline
Indications
Mechanism of action
- Coagulation factor VIIIINHIBITOR
F8 inhibitor
Partially inhibits Factor VIII activity (FVIII:C). Inhibits 40% to 70% of FVIII:C in in vitro in the presence of excess antibody.
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2109410 ↗
Also known as
- tb 402
- tb-402
- tb-402
- tb-402
- tb402 monoclonal antibody
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01344954 | Phase 2 | Apr 1, 2011 | BioInvent International AB, Oxurion NV. |
| NCT00793234 | Phase 2 | Dec 1, 2008 | BioInvent International AB, Covance, Oxurion NV. |
| NCT00618579 | Phase 1 | Feb 1, 2008 | BioInvent International AB, Cyncron Clinical Research Unit, Oxurion NV. |
| NCT00612417 | Phase 1 | Jan 1, 2008 | BioInvent International AB, Cyncron Clinical Research Unit, Oxurion NV. |
| NCT00612196 | Phase 1 | Mar 1, 2007 | BioInvent International AB, Cyncron Clinical Research Unit, Oxurion NV. |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| BioInvent International AB | For profit | 5 | 0 | 2 | 2007 |
| Oxurion NV. | For profit | 5 | 5 | 2 | 2007 |
| Cyncron Clinical Research Unit | For profit | 3 | 0 | 1 | 2007 |
| Covance | For profit | 1 | 0 | 1 | 2008 |
4 organizations
Page 1 / 1